

Financial Tear Sheet

Corporate Profile

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187[®], a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the Settlement and License Agreement and received from Biogen a non-refundable cash fee of \$1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera[®] or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 Opposition Proceedings, including any appeal thereto.

Stock Performance

FWP (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Financial Status Indicator	C
Price	\$2.11
Change (%)	0.00 (0.00%)
Volume	0
52 Week Low	\$1.64
Rolling EPS	-0.28
PE Ratio	0
Shares Outstanding	94,700,000

Data as of 10/15/18 4:00 p.m. ET



Recent Headlines

09/28/18

Forward Pharma to Participate in the Ladenburg Thalmann 2018 Healthcare Conference

09/19/18

Forward Pharma Reports Financial and Operational Results from the First Six Months of 2018

08/23/18

Forward Pharma to Participate in the LSX Nordic Congress

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
10/01/18	6-K
09/26/18	6-K
09/19/18	6-K
09/18/18	6-K

Corporate Governance

Claus Bo Svendsen, MD, PhD	CEO
Peder Møller Andersen, MD	COO

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources